Galapagos NV (GLPG)
NASDAQ: GLPG · Real-Time Price · USD
25.46
-0.04 (-0.16%)
At close: Mar 28, 2025, 4:00 PM
24.79
-0.68 (-2.65%)
Pre-market: Mar 31, 2025, 8:27 AM EDT
Galapagos NV Revenue
In the year 2024, Galapagos NV had annual revenue of 275.65M EUR with 14.99% growth. Galapagos NV had revenue of 75.50M in the quarter ending December 31, 2024.
Revenue (ttm)
275.65M EUR
Revenue Growth
+14.99%
P/S Ratio
5.88
Revenue / Employee
245,458 EUR
Employees
1,123
Market Cap
1.68B USD
Revenue Chart
* This company reports financials in EUR.
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 275.65M | 35.93M | 14.99% |
| Dec 31, 2023 | 239.72M | -1.53M | -0.63% |
| Dec 31, 2022 | 241.25M | 6.87M | 2.93% |
| Dec 31, 2021 | 234.38M | -243.67M | -50.97% |
| Dec 31, 2020 | 478.05M | -356.85M | -42.74% |
| Dec 31, 2019 | Pro | Pro | Pro |
| Dec 31, 2018 | Pro | Pro | Pro |
| Dec 31, 2017 | Pro | Pro | Pro |
| Dec 31, 2016 | Pro | Pro | Pro |
| Dec 31, 2015 | Pro | Pro | Pro |
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| UnitedHealth Group | 400.28B |
| Johnson & Johnson | 88.82B |
| Merck & Co. | 64.17B |
| AbbVie | 56.33B |
| AstraZeneca | 54.07B |
| Novartis AG | 51.72B |
| Eli Lilly and Company | 45.04B |
| Thermo Fisher Scientific | 42.88B |
GLPG News
- 3 days ago - Galapagos Publishes 2024 Annual Report and Announces Annual Shareholders' Meeting - GlobeNewsWire
- 4 weeks ago - Galapagos to Present at Upcoming Investor Conferences - GlobeNewsWire
- 5 weeks ago - Disount To Net Cash For A Promising CAR-T Company - Seeking Alpha
- 5 weeks ago - Galapagos receives transparency notification and 13D filing from Tang Capital - GlobeNewsWire
- 6 weeks ago - Galapagos NV (GLPG) Q4 2024 Earnings Call Transcript - Seeking Alpha
- 6 weeks ago - Galapagos Reports Full Year 2024 Results and Provides Fourth Quarter Business Update - GlobeNewsWire
- 2 months ago - Galapagos To Spin Off Innovative Medicines Business - Forbes
- 2 months ago - Galapagos to Unlock Shareholder Value by Declaring its Intent to Separate into Two Publicly Traded Entities - GlobeNewsWire